CorestemChemon's Global Expansion in Preclinical Services
In a significant move to enhance its global outreach, CorestemChemon is establishing a strategic partnership with ATG Lifetech. The focus of this collaboration is to implement transcriptomics-powered and organoid-based preclinical testing, paving the way for substantial advancements in drug discovery efforts worldwide.
Innovative Partnership for Preclinical Advancement
This partnership aims to create precision-driven non-clinical solutions tailored for pharmaceutical companies and biotech ventures around the globe. ATG Lifetech specializes in transcriptome analytics and organoid modeling, providing valuable insights that CorestemChemon plans to incorporate into its services.
Joint Development Focus Areas
As part of their collaborative efforts, CorestemChemon and ATG Lifetech will focus on developing:
- A transcriptome-based evaluation platform designed to accurately predict drug efficacy and safety.
- Organoid models that accurately represent diseases affecting the liver, heart, and the blood-brain barrier.
- A high-throughput transcriptomics analytics service, which aims to distinguish between real and false positives in tumorigenicity studies.
- Shared regulatory knowledge tailored for clients seeking to navigate FDA and EMA pathways effectively.
Enhanced Scientific Accuracy in Drug Testing
Through the integration of organoid-based assays, CorestemChemon aims to provide services that offer significantly higher predictive accuracy—up to five times greater—in toxicity and efficacy screening compared to traditional 2D cell cultures. This has been corroborated by industry standards and benchmarks.
Impact on Drug Development Timelines
By utilizing whole-transcriptome analyses alongside organoid systems, pharmaceutical partners can make more informed go/no-go decisions earlier in the drug pipeline. This approach not only mitigates risks associated with clinical trials but also compresses overall development timelines, making drug discovery more efficient and less costly.
Strategic Growth and Revenue Expectations
CorestemChemon is seeing this partnership as a critical component of its strategic growth plan, with an emphasis on expanding high-margin CRO services that are driven by intellectual property. Revenue-generating services are anticipated to roll out by late 2025, with projections indicating substantial global demand for these offerings.
Associated Expertise and Collaborations
ATG Lifetech contributes validated expertise gained through its international collaborations, including with ACROBiosystems, and is recognized as a core participant in various South Korean government-backed biopharma initiatives.
Future Outlook and Collaborative Showcases
Looking ahead, the two companies are preparing to showcase their joint research outcomes at a major toxicology and preclinical science conference scheduled for Q4 2025. Following this event, global service launches aimed at biotech and pharmaceutical customers in need of detailed and biologically relevant preclinical testing will commence.
CorestemChemon stands as a full-service preclinical CRO, with over two decades of expertise in GLP-compliant toxicology, pharmacokinetics, and regulatory matters. Operating multiple AAALAC-certified facilities, the company collaborates with leading biopharmaceutical innovators across various regions globally.
Frequently Asked Questions
What is the purpose of the partnership between CorestemChemon and ATG Lifetech?
The partnership aims to enhance preclinical testing capabilities using transcriptomics and organoid-based models for more accurate drug discovery outcomes.
How will this collaboration benefit pharmaceutical companies?
It will provide precision-driven non-clinical solutions that help pharmaceutical companies make informed decisions earlier in the drug development process.
What are the expected outcomes of this partnership by late 2025?
Revenue-generating services based on innovative preclinical solutions are set to launch, with a focus on meeting global demand for high-quality testing.
What innovative technologies will be developed through this collaboration?
The partnership will create transcriptome-based evaluation platforms, disease-relevant organoid models, and advanced analytics services aimed at improving drug efficacy and safety assessments.
When will the first services from this partnership be available to customers?
The initial set of services is expected to start rolling out by late 2025, following substantial research and development efforts.
